Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer

Xue-Qing Hu1, Yang Sun1, Eric Lau2, Ming Zhao1 and Shi-Bing Su1,*

Abstract: The complex pathology of cancer development requires correspondingly complex treatments. The traditional application of individual single-target drugs fails to sufficiently treat cancer with durable therapeutic effects and tolerable adverse events. Therefore, synergistic combinations of drugs represent a promising way to enhance efficacy, overcome toxicity and optimize safety. Chinese Herbal Medicines (CHMs) have long been used as such synergistic combinations. Therefore, we summarized the synergistic combinations of CHMs used in the treatment of cancer and their roles in chemotherapy in terms of enhancing efficacy, reducing side effects, immune modulation, as well as abrogating drug resistance. Our conclusions support the development of further science-based holistic modalities for cancer care.

Keywords: Cancer treatment, Chinese medicine, drug resistance, effect, immunity, side effects, synergistic combination.

INTRODUCTION

GLOBOCAN worldwide estimations indicate approximately 14.1 million new cancer diagnoses and 8.2 million cancer deaths in 2012. Furthermore, increased aging of the global population increases cancer risk, which makes cancer research more urgent than ever [1]. Cancer, which is a disease that is refractory to most current therapies, evolves progressively in an increasingly complex fashion, which is coordinated by multiple genes, proteins and their respective signal transduction pathways. Many factors work together to promote carcinogenesis and to enable initial tumor cells to acquire hallmark characteristics, including sustained proliferative signaling, replicative immortality, tumor-promoting inflammation, microenvironmental modulation, invasive and metastatic capabilities, angiogenesis, abnormal cellular energetics and the ability to avoid anti-tumorigenic mechanisms including growth suppressors, immune destruction and cell death [2].

The complexity of cancer formation and development impairs effective treatment. Current treatments for cancer include surgery, radiotherapy, chemotherapy, targeted therapy, biotherapy as well as complementary and alternative medicine (CAM) therapies such as Traditional Chinese medicine (TCM). However, none of these modalities achieves optimal curative effects without adverse events. The traditional applications of individual single-target drugs are insufficient to treat complex diseases including cancer, cardiovascular diseases or Alzheimer's disease. Investigation of new anti-cancer treatment modalities is ongoing, and novel, more tolerable synergistic drug combinations (the simultaneous application of two or more drugs that interact to enhance therapeutic effects, reduce side effects, abrogate drug resistance and to modulate anti-tumor immunity) are emerging.

Principles of drug combinations might include the following: (1) drugs working on the same target via different pathways; (2) drugs working on different targets via the same pathway; (3) drugs working on different targets via different pathways; (4) drugs working on biological networks, involving complicated interactions among multiple genes, proteins and pathways at the pharmacological and pharmacokinetic levels. Notably, network analyses of drug combinations are just beginning, as the drug-gene-protein-pathway interaction databases are still far from being completely established.

Traditional Chinese Medicine, which is based on systematic theories, exhibits several favorable advantages by synergistically balancing natural medicinal herbs to match disease complexity. TCM considers the body as a singular complex system for treatment with Chinese herbal medicines (CHMs) and Chinese herbal formulae (CHFs) under the guidance of TCM theory. Each CHM is a mixture of multiple compounds. Many CHMs are bioactive, whereas individual isolated substitutents might not exhibit bioactivity, indicating that multiple components within an herb work synergistically [3, 4]. Furthermore, formulae are more often applied in TCM. A formula generally is comprised of more multiple herbs, which are systematically arranged by a hierarchy ranking. Thus, the synergistic combinations of CHMs alone or in combination with chemotherapeutic drugs might be more applicable for the treatment of complex pathologies such as cancer. Holistic concept and syndrome differentiation in TCM theory are mainly explained in the
view of philosophy. Nowadays, modern technologies have been applied to interpret them in a reductive way. To explore the complex mechanisms of synergistic combinations and seek for material basis for synthesized action of TCM treatment, experimental studies in vitro and in vivo were firstly undertaken. Much work has been devoted and more efforts are in need.

Complex interactions among herbs or their compounds require appropriate research approaches. Extensive efforts continue to be devoted to the development of efficient treatment methods, particularly for research of combinations of CHMs. Here, we list the most commonly used experimental designs and analytical methods for investigating combinations of CHMs (Table 1).

### SYNERGISTIC EFFECTS OF CHM COMPOUNDS, CHMS COMBINATIONS AND CHFS IN CANCER TREATMENTS

As previously mentioned, cancer cells can acquire ten “hallmarks” as originally proposed by Douglas Hanahan and Robert A. Weinberg [2]. Literature to date indicates that synergistic combinations of CHMs can downregulate proliferative signaling, inhibit tumor angiogenesis, promote cell death and inhibit invasion and metastasis. Normal tissues are capable of switching precisely regulating both growth-promoting and apoptosis-inducing signals to maintain cellular population. Thus, restoring normal proliferative activity represents one approach at treating cancer. Cell death, in the form of apoptosis, autophagy and necrosis, counteracts cellular overgrowth. Cancer cells can effectively escape such processes and exhibited unrestrained proliferation. Studies have demonstrated that autophagy can bi-directionally promote cellular survival and death [27]. Necrosis is not necessarily beneficial, as necrotic cells can release bioactive factors to induce the proliferation of neighboring cells, and can furthermore, attract inflammatory cells to consume or remove necrotic debris, which can facilitate tumorigenesis [28, 29]. As the roles of autophagy and necrosis are controversial in cancer, anti-cancer drug investigations have predominantly focused on apoptotic mechanisms. Angiogenesis represents another trait of cancer cells, as tumors require sufficient vasculature to acquire nutrients and to eliminate waste. Invasion and metastasis represents another basic trait of cancer cells as they progress to malignancy. This process affects both cellular morphology as well as reduces adhesion to stromal cells and to the extracellular matrix (ECM). Based on those hallmarks, synergistic combinations of CHM compounds and CHMs and CHFs were performed.

### Synergistic Combinations of CHM Compounds

CHM compounds are bioactive, and studies of synergistic combinations of CHM compounds for the treatment of cancer have predominantly focused on curcumin, querctin and resveratrol-based combinations.

Curcumin is the main active component of turmeric (Curcuma longa L.), which is a member of the ginger (Zingiberaceae) family. Curcumin has been reported to exhibit anti-inflammatory, antioxidant and chemotherapeutic effects and does not elicit toxicity in laboratory animals even at high doses [30, 31]. Curcumin acts on the expression of tumor suppressor genes, apoptotic genes, oncogenes, and their respective proteins and signal pathways [32]. Several CHM compounds have been combined with curcumin to enhance treatment efficacies. In vitro and in vivo studies have shown that curcumin and resveratrol combinations can enhance apoptotic effects in the head and neck carcinomas cells, including upregulation of PARP-1 cleavage and Bax/Bcl-2 ratio and downregulation of ERK1 and ERK2 phosphorylation. Those effects were elicited more significantly by the combination treatments than that by treatment with the application of curcumin alone [33]. Curcumin has also been combined with triptolide to promote apoptosis in ovarian cancer cells, accompanied by HSP27 and HSP70 down regulation [34]. In addition, the combination of curcumin and emodin was reported to decrease the proliferative and migratory ability of breast cancer cells [35]. Different combinations of CHM compounds with curcumin have achieved similar and different biological effects in cancers, as detailed in Table 2.

Resveratrol exhibits a range of beneficial activity, including chemoprevention and anti-tumor effects [36].

### Table 1. Designs and analysis methods for CHMs combination.

| CHM Combinations | Experimental Designs | Analysis Methods and Models | Refs. |
|------------------|----------------------|-----------------------------|-------|
| Herbal pairs     | uniform design, fixed ratio design | F-test, high-dimensional B-splines, loewe additivity, bliss independence, nonlinear mixed-effects modeling, combination index method and isobologram techniques, Combo method, target inhibition networks, curve-shift analysis, surface of synergistic interaction analysis, separate ray model, pharmacokinetic-pharmacodynamic model and additive damage model | [5-13] |
| Multiple drugs   | factorial design, uniform design | semi-parametric response surface model, response surface model, combination index method, isobologram techniques, standard FIC index model, target inhibition networks, formal model, network topology analysis, drug Combo Ranker, emax model and bivariate thin plate splines | [6, 9, 14-22] |
| Formula          | Uniform design, orthogonal design | systems-pharmacological and distance-based mutual information models, chemometric techniques, prediction pharmacodynamics model | [23-26] |
Table 2. Synergistic combinations of CHM compounds.

| CHM Compound 1 | CHM Compound 2 | Effects | Mechanisms | Cancers | Refs. |
|----------------|----------------|---------|------------|---------|-------|
| Curcumin       | resveratrol    | ↑apoptosis; ↓proliferation | ↑antioxidant enzymes, PARP-1 cleavage, Bax/Bcl-2 ratio, p53 activation; ↓enzyme activities of drug-metabolizing enzymes, ERK1 and ERK2 phosphorylation, LC3 II, XIAP and survivin expression, NF-kappaB activity, p-Akt, cyclin D1 | lung cancer, head and neck carcinoma, hepatocellular carcinoma, breast cancer, colon cancer, prostate cancer, neuroblastoma. | [33, 51-55] |
|                | triptolide     | ↑apoptosis | ↑ HSP27 and HSP70 | ovarian cancer | [34] |
|                | emodin         | ↓ proliferation, invasion | ↑ miR-34a ; ↓ TGF-β signaling pathway | breast cancer, cervical cancer | [35, 56] |
|                | arctigenin+green tea polyphenol | ↓ proliferation, migration | ↑ Bax/Bcl-2 ratio; ↓ NF kappaB, PI3K/Akt and Stat3 pathways | prostate cancer, breast cancer | [57] |
|                | arctigenin     | ↓ programmed cell death; ↓ metastasis, proliferation, angiogenesis. | ↓ AR and PI3K/Akt pathways and oncogenic microRNAs | prostate cancer | [42] |
|                | hyperoside     | ↑ S-phase arrest, G2/M-phase arrest and apoptosis | ↓ S-phase kinase protein 2 and Her2 expression | breast cancer | [58] |
|                | resveratrol    | ↓ proliferation survival and angiogenesis | ↓ oncogenic microRNA-27a, phosphorylation of Akt | colon cancer, glioma | [45, 59] |
| Quercetin      | EGCG/green tea polyphenols | ↓ proliferation | ↑ bioavailability, intracellular concentration of EGCG; ↓ methylation of green tea polyphenols | prostate cancer | [60, 61] |
| Paclitaxel     | curcumin       | ↑apoptosis; ↓proliferation, drug resistance | ↓ EGFR signaling, NF-κB activity, glycogen synthase kinase-3 | breast cancer, hepatocarcinoma, cervical cancer, ovarian cancer, brain tumor | [62-66] |
| Taxifolin      | andrographolide | ↑ mitotic arrest and apoptosis | disrupting microtubule dynamics and activating the spindle assembly checkpoint | prostatic cancer | [67] |
|                | matrine        | ↑apoptosis; ↓proliferation | ↑ caspase-3 and caspase-9; ↓ survivin | hepatoma | [39] |
| Resveratrol    | arsenic trioxide | ↑ apoptosis, angiogenesis | ↑ poly (ADP-ribose) polymerase, (PARP) and its cleaved isoform | ovarian cancer, breast cancer, acute or chronic myeloid leukemia cells, lung adenocarcinoma | [40, 68, 69] |
|                | genistein      | ↑ apoptosis; ↓ drug resistance | ↑ caspase cascade; ↓ expression of HDM2, MRP2 | ovarian cancer, cervical cancer, liver cancer, prostate cancer | [41, 70, 71] |
| Artesunate     | triptolid      | ↑apoptosis | ↑ HSP 20 and HSP 27 | pancreatic cancer | [72] |
|                | alicin         | ↑apoptotic rate; ↓ viability, invasion, motility and colony formation ability | ↑ caspase-3/9 | osteosarcoma | [73] |
| Arsenic trioxide | berberine      | ↑apoptosis cell; ↓ viability | ↑ caspase-3; ↓ Bcl-2, Bid, Bcl-x/L, PKC-mediated signaling pathway | neuroblastoma, glioma | [74, 75] |
|                | salvianolic acid B | ↑apoptosis | ↓ Bcl-2, p-Akt | hepatoma and breast cancer | [76] |

↑: Up-regulation
↓: Down-regulation
Synergistically combining resveratrol and tanshinone IIA at a ratio of 1:1 or 1:2 induced cisplatin-comparable cytotoxicity in hepatocellular carcinoma cells. The proportion of apoptosis (sub-G1 cell cycle accumulation) and DNA fragmentation were increased more significantly by the combination compared to single-agent treatments [37]. Resveratrol elicited more significant inhibitory effects on ovarian and hepatocellular carcinoma cells when combined with artemisinin at a ratio of 2:1 by increasing apoptosis, ROS levels and by decreasing migratory ability [38]. Combinations of resveratrol with matrine, genistein and arsenic trioxide have been used in the treatment of hepatoma, breast cancer and acute and chronic myeloid leukemias [39-41].

Quercetin is another commonly used CHM compound and is found in many fruits, vegetables and grains. Generally, quercetin has been applied in combined with arctigenin, hyperoside and resveratrol. These combinations have improved anti-cancer effects compared to the application of the individual agents by regulating proliferation, migration, angiogenesis and apoptosis processes in prostate cancer, leukemia, breast cancer and pancreatic cancer cell lines [42-45].

Both baicalin and baicalein are CHM compounds that are extracted from Huangqin (Scutellaria baicalensis), an herb that is commonly used to treat cardiovascular diseases, hypertension and cancer [46]. The combination of these two herbal compounds elicited more significant induction of apoptosis in human breast cancer cells compared with the application of either agent alone. Synergistic effects were achieved in terms of ERK / p38 MAPK activation, as well as activation of caspases-3, caspase-9, Bel-2, Bax and p53 [47]. Zuojinwan has been reported to inhibit the growth of hepatocellular carcinoma [48]. Further studies have shown that the active components of Zuojinwan, berberine and evodiamine, can synergistically promote cancer cell apoptosis in vitro [49]. A docking analysis has shown that panaxadiol and epigallocatechin gallate can synergistically impair the proliferation of human colorectal cancer cells, as these two compounds bind to two different sites of the annexin V protein [50]. Other CHM combinations, including taxifolin with andrographolide, triptolid with artesunate, artesunate with allicin, evodiamine with norcantharidin, or berberine with arsenic trioxide are listed in Table 2. Most CHM compound combinations are currently in the experimental stage of pre-clinical studies. Further investigation is warranted to clearly understand the crosstalk between CHM compounds.

As shown in Table 2, actions of curcumin-based combinations were tested on different cell lines, especially on prostate and breast cancers and studies has shown apparent efficacy via different mechanisms. Among them, combinatorial use of curcumin and resveratrol was most widely studied in diverse cancers. Queretin-based combinations were mainly explored on prostate cancer and has significantly enhanced the therapeutic effect. Additionally, resveratrol-based combinations in different experiments demonstrated good effects on ovarian cancer cells. To seek for the best CHM combinations for certain kind of cancers and determine the tissue context dependence, more studies on diverse cancers should be taken.

Synergistic Effects of CHMs Combinations

CHMs combinations represent the core of CHFs. TCM physicians combine CHMs to enhance therapeutic effects and alleviate toxicity and side effects.

Yanhusuo (Rhizoma corydalis) extract has been reported to weaken the invasiveness and metastatic capacity of breast cancer cells. Furanodiene, which is isolated from Ezhu (Rhizoma curcumae), has been reported to elicit anti-proliferative effects and apoptosis in lung cancer cells [77, 78]. Further investigation of the synergistic effects of Ezhu and Yanhusuo indicated that combination treatments of Ezhu and Yanhusuo at a ratio of 3:2 could reduce the proliferative and invasive capacities of breast cancer cells more significantly and induce more cytochrome c release (which initiates apoptosis) than the individual treatment with either Ezhu or Yanhusuo. Furthermore, one of the synergistic mechanisms regulating p-ERK level was reduced [79].

Another study demonstrated that the actions of Juhua (Dendranthema morifolium) and Donglingcao (Rabdosia rubescens) are additive, as are those of Huangqin (Scutellaria baicalensis) and Juhua, suggesting that the combination of these herbs work on similar molecular targets or metabolic pathways. However, combinations of Huangqin and Gancao (Guralensis), Huangqin and Donglingcao, Gancao and Donglingcao, Gancao and Juhua have been reported to exhibit antagonistic effects on the viability of prostate cancer cell lines in vitro, whereas the combination of all four herbal extracts inhibited cancer cell growth more significantly compared to their individual application alone. However, further investigations on the underlying mechanisms are needed [80].

Cili (Rosa roxburghii tratt) and Jingqiaomai (Fagopyrum cymosum) have been combined to suppress proliferation and promote apoptosis of esophageal squamous carcinoma, gastric carcinoma and pulmonary carcinoma cells in vitro, predominantly by increasing Bax levels and reducing Bel-2 expression [81]. Another study showed that Lingzhi (Ganoderma lucidum) potentiated the cytotoxic effects of Yunzhi (Coriolus versicolor) on leukemia cells. Treatment with this combination also resulted in reduced Rb phosphorylation and increased poly (ADP–ribose) polymerase (PARP) cleavage [82].

Synergistic Effects of CHFs

CHFs are composed of several CHMs, each of which plays a different role (e.g., monarch, minister, assistant or guide according to CHF-construction principles in TCM). The effects of each ingredient in CHF are not additive in an accumulative fashion but rather interact with each other intricately to enhance curative effects and reduce undesirable effects.

For example, the logically constructed formula Fufang qingdai pill (Realgar-Indigo naturalis formula) is commonly used to treat acute promyelocytic leukemia (APL). The formula consists of Xionghuang (Realgar), Qingdai (Indigo naturalis) and Danshen (Salvia miltiorrhiza), as directed by CHF construction principles. Three main active compounds, tetraarsenic tetrasulfide, indirubin and tanshinone IIA, were
Thus, the improvement of immunity represents a therapeutic prolonging lifespan effects, ultimately improving patient quality of life and chemotherapy, potentiates the cytotoxicity induced by CHFs enhances immunity and improves tolerance to results. The proper addition of CHM compounds, CHMs or CHFs with chemotherapeutics has yielded encouraging approaches on CHF researches. Conversely, adverse events, including nausea, vomiting, and anorexia, often accompany chemotherapy. Therefore, relieving side effects represents a significant rationale for the application of CHMs during chemotherapy. The additive use of astragalus polysaccharide significantly alleviated side effects including fatigue, nausea and vomiting, pain and loss of appetite associated with treatment with vinorelbine and cisplatin chemotherapy for patients with advanced non-small cell lung cancer and their median survival time was also prolonged [90]. Another CHF injection, Shenqi fuzheng injection has also been reported to be effective against non-small cell lung cancer. A meta-analysis covering 2062 patients demonstrated that the efficiency of platinum-based chemotherapy was enhanced by intravenous dripping of Shenqi fuzheng injection [91]. A another randomized and controlled clinical trial evidenced that the injection also increased the curative effects of cyclophosphamide, epirubicin and 5-fluorouracil regime, accompanied with the growth of T-lymphocyte subgroup and NK cells for local advanced breast cancer patients [92]. A systematic review demonstrated that astragalus-based Chinese herbs enhanced the inhibitory effects of platinum-based chemotherapy in advanced non-small-cell lung cancer [93].

SYNERGISTIC EFFECTS AND UNDERLYING MECHANISMS OF CHM COMPOUNDS, CHM OR CHFS RESPECTIVELY COMBINED WITH CHEMOTHERAPEUTIC DRUGS IN THE TREATMENT OF CANCER IN CLINICAL

The combinational use of CHM compounds, CHM or CHFs with chemotherapeutics has yielded encouraging results. The proper addition of CHM compounds, CHMs or CHFs enhances immunity and improves tolerance to chemotherapy, potentiates the cytotoxicity induced by chemotherapeutic drugs, and largely alleviates their side effects, ultimately improving patient quality of life and prolonging lifespan.

Previous research has demonstrated that competent immune systems can significantly reduce tumor incidence and development, resulting in improved prognosis [84]. Thus, the improvement of immunity represents a therapeutic approach to impair and even arrest tumor progression. In a clinical trial on 105 patients, a mixture of citronella isolated from Tianzhukui (Geranium) and extracts from Lingzhi (Ganoderma lucidum), Danshen (Codonopsis pilosula) and Donggul (Angelicae sinensis) could apparently reduce the leukocyte depletion for cancer patients undergoing chemotherapy or radiotherapy. The mixture modulated the immunity to help the body fight against cancer cells [85]. A double-blind placebo-controlled randomized trial on patients with ovarian cancer showed that additive use of TCM to conventional chemotherapy indeed had less decreased lymphocyte counts, which helped to keep patients' tolerance to further therapy [86].

CHM compounds, CHMs or CHFs might significantly enhance the cytotoxic effects of chemotherapeutic drugs. A prospective, phase II study on patients with elapsed or refractory multiple myeloma showed that the efficacy of melphalan was improved when treated in combination with ascorbic acid and arsenic trioxide [87]. Combinatorial use of trumeric powder and imatinib decreased the nitric oxide (NO) levels in chronic myeloid leukemia more obviously than imatinib used alone and the NO has been found to be associated with angiogenesis [88, 89]. The combination of Shengnai injection and Gujín granule were reported to potentiate the short-term cytotoxicity induced by navelbine and cisplatin chemotherapy for patients with advanced non-small cell lung cancer and their median survival time was also prolonged [90]. Another CHF injection, Shenqi fuzheng injection has also been reported to be effective against non-small cell lung cancer. A meta-analysis covering 2062 patients demonstrated that the efficiency of platinum-based chemotherapy was enhanced by intravenous dripping of Shenqi fuzheng injection [91]. A another randomized and controlled clinical trial evidenced that the injection also increased the curative effects of cyclophosphamide, epirubicin and 5-fluorouracil regime, accompanied with the growth of T-lymphocyte subgroup and NK cells for local advanced breast cancer patients [92]. A systematic review demonstrated that astragalus-based Chinese herbs enhanced the inhibitory effects of platinum-based chemotherapy in advanced non-small-cell lung cancer [93].
Resveratrol were found to alleviate the cardiotoxicity induced by doxorubicin [100]. The additive use of TCM to chemotherapy was able to protect the liver, resulting in lower serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels than chemotherapy used alone [101]. Mistletoe extract and arsenic trioxide were applied more in clinical to reduce the adverse effects caused by chemotherapy (Table 3).

To explore the cellular mechanisms under those combinations, great amount of studies on cancer cell lines were undertaken and the modes of CHMs interacting with chemotherapeutic drugs were summarized as follows: (1) inhibit cancer cell growth and reduce dosages of chemotherapeutic drugs to achieve equivalent or enhanced curative effects, consequently reducing drug-induced adverse events; (2) create new inhibitory effects when combined with chemotherapy drugs; (3) improve the patient immunity enhance tolerance for further chemotherapy; (4) act as chemotherapeutic drug sensitizer; (5) help the absorption of drugs to enhance the drug effects (for example, curcuma increased the absorption of rhizoma paridis spooning to enhance anti-tumor effects [102]. Notably, individual herbs or CHM compounds might participate via several modes. For example, ursoic acid enhances the curative effects of capetitabine by downregulating multiple tumor-related inflammation, proliferation, invasion, angiogenesis and metastasis mechanisms [103].

Currently, most of researches are still in the experimental stage and quite limited clinical trials are available to precisely evaluate CHM compounds, CHMs or CHFs’ contribution to conventional chemotherapy. Presently CHMs and CHFs are rarely used alone in the treatment of cancer in clinical and mainly act as a supplementary and adjunctive strategy due to their insignificant or unconfirmed antitumoral efficacy. Even when used in combination with conventional chemotherapy occasionally, a limited efficacy has been

### Table 3. Synergistic combinations of CHM compounds or CHMs with chemotherapeutic drugs in clinical.

| CHM Compounds/CHMs     | Chemotherapeutic Drugs                          | Designs                                      | Case Numbers | Cancers                          | Clinical Outcomes                                      | Refs. |
|------------------------|--------------------------------------------------|----------------------------------------------|--------------|----------------------------------|--------------------------------------------------------|-------|
| **Arsenic trioxide**   | ascobic acid+melphalan                            | prospective, multicentre, single-arm         | 65           | multiple myeloma                 | ↑ therapeutic effect and tolerance                      | [104] |
|                        | all-trans retinoic acid                          | randomized, controlled                       | 61           | acute promyelocytic leukemia     | ↓ quality of complete remission, the status of the disease-free survival | [105] |
|                        | dexamethasone+ascobic acid                       | a phase 2 trial.                             | 20           | multiple myeloma                 | ↑tolerance; ↓ adverse events                            | [106] |
| **Mistletoe extract**  | cyclophosphamide + adriamycin +cisplatin          | Prospective, Randomized, Controlled          | 68           | breast cancer                    | ↑ quality of life; ↓ reduce the side-effects           | [107] |
|                        | cyclophosphamide +cisplatin/irosfamide +carboptatin | A Prospective Randomized Controlled Clinical Trial | 71           | ovarian cancer                   | ↑ quality of life; ↓ reduce the side-effects           | [107] |
|                        | vinorelbine +cisplatin/mitomycine+vindesine +cisplatin | A Prospective Randomized Controlled Clinical Trial | 94           | non-small cell lung cancer       | ↑ quality of life; ↓ reduce the side-effects           | [107] |
|                        | cyclophosphamide+methotrexate+fluorouracil       | randomised, placebo-controlled, double-blind, multicentre | 272          | breast cancer                    | ↑ quality of life                                      | [108] |
|                        | cisplatin+5-fluorouracil/5-fluorouracil          | randomized, controlled                       | 20           | ear, nose and throat carcinoma   | ↑ immunological reactions, microcirculation            | [109] |
| **Turmeric powder**    | imatinib                                         | randomized, controlled                       | 50           | chronic myeloid leukemia         | ↑ therapeutic effect                                   | [88]  |
| **Astragalus polysaccharide injection** | vinorelbine and cisplatin                         | randomized, controlled                       | 136          | non-small cell lung cancer       | ↑ therapeutic effect, quality of life; ↓ reduce the side-effects | [110] |
| **Cimicifuga racemosa** | tamoxifen                                        | prospective                                  | 50           | breast cancer                    | ↓ psychovegetative symptoms                             | [111] |
| **Scutellaria baicalensis** | irinotecan                                       | randomized, controlled                       | 44           | non-small cell lung cancer       | ↓ gastrointestinal toxicity                             | [112] |

↑: Up-regulation  
↓: Down-regulation
achieve synergistic efficacy; for example, CHMs or CHFs with or without chemotherapy might fail to interact (Table 4 reports has evidenced the severe risk of Chinese herb-drug interactions (Table 4). Therefore, more reliable studies and methods should be applied to evaluate the actions of CHM-related combinations on cancer treatment prudently and objectively.

### UNWANTED SIDE EFFECTS OF SYNERGISTIC COMBINATIONS

Actually, the concomitant use of CHM compounds, CHMs or CHFs with or without chemotherapy might fail to achieve synergistic efficacy; for example, kanglaite didn’t bring about additional benefits to patients with advanced breast cancer receiving mitomycin-C or cisplatin [113]. What’s worse, not all combinations are free from harm. Some combinations may interfere with the metabolism of concurrently used drugs, consequently compromising the chemotherapy’s efficacy, even increasing risks of hepatotoxicity, nervous system damage, or reduced curative effects (e.g., via herb-drug interaction) [114]. Siwutang reversed the anti-proliferative effects of tamoxifen and increased levels of estrogen receptor alpha and N-cadherin. However, this formula was also reported to attenuate the anti-proliferative activity of trastuzumab by increasing the phosphorylation of the cell cycle regulatory protein p27 (Kip1) [115]. A combination of Baihuasheshecao and Dihuang was reported to inhibit the expression of CYP3A4, another drug antiporter, consequently increasing the potential toxicity of drugs and narrowing the therapeutic window [116]. More examples were listed in Table 4. As the CHM-CHM or CHM-drug interaction is complicated and the mechanisms largely remain obscure. In addition to the desired curative effects, potential unintended side effects deserve equal attention.

### PERSPECTIVES AND CONCLUSIONS

The complex biology of cancer development requires relatively complex treatment approaches. Cancer development involves multiple genes, proteins and pathways, as well as intricate crosstalk among them. Thus, the application of synergistic combinations of drugs has emerged as a therapeutic approach and continues to play an important role in the treatment of cancer, particularly in terms of combination of CHMs, which are unique in their formulae and applications. The application of synergistic combinations of CHMs for the treatment of cancer has produced intended therapeutic effects, particularly when combined with chemotherapy, in terms of enhancement of curative effects, reduction of adverse events associated with conventional therapies, improvement of patient immunity, eventually promoting patient rehabilitation, improving quality of life and prolonging their lifespan.

Enhanced therapeutic efficacy produced by combinations of CHM compounds, CHMs and CHFs were generally achieved via inducing apoptosis, reducing proliferation, migration and angiogenesis, as well as altering cell cycle dynamics and cell viability by regulating relevant gene expression and protein signaling pathways in many kinds of cancer cell lines according to pre-clinical researches. However, in clinical their efficacy was compromised. There is a big discrepancy between experimental data and clinical use. Main reasons may includes: (1) the human body works intricately and the cancer complicates the complexity; (2) CHMs or CHFs contains many ingredients and there are inherently complex interactions among those ingredients in a single herb or formula, especially when they entered into the body; (3) the microenvironment of cancer cells in the body might also affect cells’ response to herbs or drugs. But such microenvironment is hard to imitate in vitro; (4) cancer cells in the body develops gradually and continuously; however, cells lines in vitro are in a relatively stable condition. Therefore, experimental and clinical results might not be consistent; (5) some studies either in pre-clinical or clinical are of low quality; (6) in China, only being approved as new drugs, can these CHM compounds be studied in clinical legally. To overcome those limitations, firstly, more efficient and reliable methods for researching as well as estimating the synergistic effects of CHMs-related combinations should be optimized, like the network-based approach, pharmacological networks [122]. Secondly, studies of high quality, especially in clinical are needed. Thirdly, apart from exploring the association of certain genes, proteins or pathways with synergistic combinations, explaining the roles of tumor-promoting inflammatory microenvironment and abnormal energy metabolism and how they are interfered by herb-herb or herb-drug combinations should be emphasized. Additionally, mechanisms of CHMs and CHFs action needs to be revealed to find a critical point that correlates cancer initiation or progression processes to herbs or drugs’ targets.

---

### Table 4. Combinations of CHM compounds/CHMs/CHF with chemotherapeutic drugs that elicited have adverse events.

| CHMs Compounds/CHMs/CHFs | Chemotherapeutic Drugs | Cancers | Adverse Events | Study Types | Refs. |
|--------------------------|------------------------|---------|----------------|-------------|-------|
| Songrong (Agaricus blazei) | cisplatin+cyclophosphamide | ovarian cancer | hepatotoxicity | case report | [117] |
| Renshen (ginseng)+selenium | gefitinib | lung adenocarcinoma | disease progression speeding | case report | [118] |
| Injections of Nerium oleander | ifosfamide+etoposide | knee synovial carcinoma | hepatotoxicity, cardiopulmonary arrest | case report | [119] |
| Amygdalin+vitamin C | cisplatin+gemcitabine | bladder urothelial carcinoma | tachycardia, tonic–clonic seizures | case report | [120] |
| Xanthorrhizol | tamoxifen | breast cancer | promote tumor growing | experimental study | [121] |
Unveiling the tissue context dependence of CHMs-related combinations is also on the agenda. So a far way lies ahead to bridge the gap between experimental data and clinical application.

CONFLICT OF INTEREST

All authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by Key Program of National Natural Science Foundation of China (81330084), and E-institutes of Shanghai Municipal Education Commission (No E 05008).

REFERENCES

[1] Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65(2), 87-108.
[2] Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
[3] Foungbe, S.; Kouassi, G.; Kablan, J.B.; Marcy, R. Study of Costus luicanusianus: plant juice, fraction combinations and pharmacologic estimation of natural product total activity. J. Ethnopharmacol., 1991, 33(3), 221-226.
[4] Schuster, B.G. A new integrated program for natural product development and the value of an ethnomedical approach. J. Altern. Complement. Med., 2001, 7(Suppl 1), S61-S72.
[5] Boik, J.C.; Newman, R.A.; Boik, R.J. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat. Med., 2008, 27(7), 1040-1061.
[6] Feng, H.B.; Ross, D.D.; Sausville, E.; Tan, M. Experimental design and interaction analysis of combination studies of drugs with non-linear dose responses. Stat. Med., 2008, 27(16), 3071-3083.
[7] Nakata, H.; Steinberg, S.M.; Koh, Y.; Maeda, K.; Takaoka, Y.; Tamamura, H.; Fujii, N.; Mitsuya, H. Potent synergistic anti-human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3’-azido-3’-deoxycytidine, phosphonoformate, and 2’,3’-dideoxycytidine. Antimicrob. Agents Chemother., 1991, 35(10), 2003-2011.
[8] Deciga-Campos, M.; Lopez, U.G.; Reval, M.I.; Lopez-Munoz, F.J. Target inhibition networks: predicting selective combinations of drugable targets to block cancer survival pathways. PLoS Comput. Biol., 2009, 5(9), e1003226.
[9] Deciga-Campos, M.; Lopez, U.G.; Reval, M.I.; Lopez-Munoz, F.J. Enhancement of antineoplastic co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats. Eur. J. Pharmacol., 2003, 460(2-3), 99-107.
[10] Strakemans, R.; Bijvens, L. Application and review of the separate ray model to investigate interaction effects. Front. Biosci. (Elite Ed), 2010, 2, 266-278.
[11] Terranova, N.; Germani, M.; Del Bene, F.; Magni, P. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination. Cancer Chemother. Pharmacol., 2013, 72(2), 471-482.
[12] Jones, L.B.; Secomb, T.W.; Dewhirst, M.W.; El-Kareh, A.W. The additive damage model: a mathematical model for cellular responses to drug combinations. J. Theor. Biol., 2014, 357, 10-20.
[13] Rockhold, F.W.; Goldberg, M.R. An approach to the assessment of therapeutic drug interactions with fixed combination drug products. J. Biopharm. Stat., 1996, 6(3), 231-240.
[14] Bull, R.J.; Sasser, L.B.; Lei, X.C. Interactions in the tumor-promoting activity of carbon tetrachloride, trichloroacetic, and dichloroacetic in the liver of male B6C3F1 mice. Toxicology, 2004, 199(2-3), 169-183.
[15] Coffey, T.; Gennings, C.; Simmons, J.E.; Herr, D.W. D-optimal experimental designs to test for departure from additivity in a fixed-ratio mixture ray. Toxicol. Sci., 2005, 88(2), 467-476.
[16] Kong, M.; Lee, J.J. A semiparametric response surface model for assessing drug interaction. Biometrics, 2008, 64(2), 396-405.
[17] Meletiadis, J.; Verweij, P.E.; DeRortshorst, D.T.; Meis, J.F.; Mouton, J.W. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol., 2005, 43(2), 133-152.
[18] Kaw, H.; Zhang, B.; Li, S.; Zhao, Q. A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NF-kappaB pathway. BMC Syst. Biol., 2010, 4, 50.
[19] Huang, L.; Li, F.; Sheng, J.; Xia, X.; Ma, J.; Zhan, M.; Wong, S.T. DrugCombinerRanker: drug combination discovery based on target network analysis. Bioinformatics, 2014, 30(12), i228-i236.
[20] Kong, M.; Lee, J.J. Applying Emmax model and bivariate thin plate splines to assess drug interactions. Front. Biosci. (Elite Ed), 2010, 2, 279-292.
anticancer activity in vitro. Evid. Based Complement. Altern. Med., 2013, 2013, 759483.

[77] Gao, J.L.; Shi, J.M.; He, K.; Zhang, Q.W.; Li, S.P.; Lee, S.M.; Wang, Y.T. Yanshuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways. J. Ethnopharmacol., 2008, 118(3), 819-824.

[78] Xu, W.S.; Dang, Y.Y.; Guo, J.J.; Wu, G.S.; Lu, J.J.; Chen, X.P.; Wang, Y.T. Furandione induces endoplasmic reticulum stress and presents antiproliferative activities in lung cancer cells. Evid. Based Complement. Altern. Med., 2012, 2012, 462521.

[79] Gao, J.L.; He, T.C.; Li, Y.B.; Wang, Y.T. A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcuma exerts synergistic anti-tumor activity. Oncol. Rep., 2009, 22(5), 1077-1083.

[80] Adams, L.S.; Seeram, N.P.; Hardy, M.L.; Carpenter, C.; Heber, D. Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines. Evid. Based Complement. Altern. Med., 2006, 3(1), 117-124.

[81] Liu, W.; Li, S.Y.; Huang, X.E.; Cui, J.J.; Zhao, T.; Zhang, H. Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac. J. Cancer Prev., 2012, 13(5), 2409-2414.

[82] Hsieh, T.C.; Wu, J.M. Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by the combination of Curcumin versicolor and Ganoderma lucidum. Int. J. Mol. Med., 2013, 32(1), 251-257.

[83] Wang, L.; Zhou, G.B.; Liu, P.; Song, J.H.; Liang, Y.; Yan, X.J.; Xu, F.; Wang, B.S.; Mao, J.H.; Shen, Z.X.; Chen, S.J.; Chen, Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 2008, 105(12), 4826-4831.

[84] Bindea, G.; Mlecnik, B.; Fridman, W.H.; Pages, F.; Galon, J. Immunological monitoring of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a phase II/I study of PHY906/capcitabine in advanced hepatocellular carcinoma. Anticancer Res., 2009, 29(10), 4083-4092.

[85] Wang, J.C.; Tian, J.H.; Ge, L.; Gan, Y.H.; Yang, K.H. Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta-analysis of randomized controlled trials. Asian Pac. J. Cancer Prev., 2014, 15(12), 4795-4800.

[86] Farrell, M.P.; Kummer, S. Phase IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer, 2003, 2(4), 253-256.

[87] Sin, T.K.; Tam, B.T.; Yung, B.Y.; Yip, S.P.; Chan, L.W.; Wong, C.S., Ying, M.; Rudd, J.A.; Siu, P.M. Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J. Physiol., 2015, 593(8), 1887-1899.

[88] Liu, M.L.; Chien, L.Y.; Tai, C.J.; Lin, K.C.; Tai, C.J. Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients. Evid. Based Complement. Altern. Med., 2011, 2011, 291843.

[89] Man, S.; Li, Y.; Fan, W.; Gao, W.; Liu, Z.; Li, N.; Zhang, Y.; Liu, C. Curcuma increasing antitumor effect of Rhizoma paridis saponins through absorptive enhancement of paridis saponins. Int. J. Pharm., 2013, 454(1), 296-301.

[90] Prasad, S.; Yadav, V.R.; Sung, B.; Reuter, S.; Kannappan, R.; Deourukhar, A.; Diagaradjane, P.; Wei, C.; Baldwinathanapai, V.; Krishnan, S.; Guha, S.; Aggarwal, B.B. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capcitabine. Clin. Cancer Res., 2012, 18(18), 4942-4953.

[91] Berenson, J.R.; Boccia, R.; Siegel, D.; Bozdech, M.; Bessudo, A.; Stadtmueller, E.; Talisman, P.J.; Steis, R.; Flam, M.; Lutzky, J.; Jilani, S.; Volk, J.; Wong, S.F.; Moss, R.; Patel, R.; Ferrer, D.; Russell, K.; Louie, R.; Yeh, H.S.; Swift, R.A. Efficacy and safety of melphalan, arsanic trioxide combination chemotherapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br. J. Haematol., 2006, 135(2), 174-183.

[92] Ghaliut, V.S.; Sangwan, L.; Daihya, K.; Ghaliut, P.S.; Dhanhar, R.; Saharan, R. Effect of imatinib therapy with and without tumoric powder on nitric oxide levels in chronic myelocid leukemia. J. Oncol. Pharm. Pract., 2012, 18(2), 186-190.

[93] Jadeski, L.C.; Chakraborty, C.; Lala, P.K. Role of nitric oxide in tumour progression with special reference to a murine breast cancer model. Can J. Physiol. Pharmacol., 2002, 80(2), 125-135.

[94] Chen, Y.Z.; Li, Z.D.; Gao, F.; Zhang, Y.; Sun, H.; Li, P.P. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. Chin. J. Integr. Med., 2009, 15(6), 415-419.

[95] Dong, J.; Su, S.Y.; Wang, M.Y.; Zhan, Z. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J. Exp. Clin. Cancer Res., 2010, 29, 137.

[96] Dai, Z.; Wan, X.; Kang, H.; Ji, Z.; Liu, L.; Liu, X.; Song, L.; Min, W.; Ma, X. Clinical effects of Shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J. Tradit. Chin. Med., 2008, 28(1), 34-38.
multicentre clinical trial. **Anticancer Res.**, 2004, 24(2C), 1293-1302.

[109] Klopp, R.; Schmidt, W.; Werner, E.; Werner, M.; Niemer, W.; Beuth, J. Influence of complementary Viscum album (Isca dor) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. **Anticancer Res.**, 2005, 25(1B), 601-610.

[110] Guo, L.; Bai, S.P.; Zhao, L.; Wang, X.H. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. **Med. Oncol.**, 2012, 29(3), 1656-1662.

[111] Rostock, M.; Fischer, J.; Mumm, A.; Stammpitz, U.; Saller, R.; Bartsch, H.H. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study. **Gynecol. Endocrinol.**, 2011, 27(10), 844-848.

[112] Mori, K.; Kondo, T.; Kamiyama, Y.; Kano, Y.; Tominaga, K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. **Cancer Chemother. Pharmacol.**, 2003, 51(5), 403-406.

[113] Guo, H.Y.; Cai, Y.; Yang, X.M.; Wang, Z.H.; Wang, J.L.; Zhao, X.M.; Li, J.; Hu, X.C. Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer. **Am. J. Chin. Med.**, 2008, 36(4), 665-674.

[114] Yap, K.Y.; See, C.S.; Chan, A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. **Recent Pat. Food Nutr. Agric.**, 2010, 2(1), 12-55.

[115] Chen, J.L.; Wang, J.Y.; Tsai, Y.F.; Lin, Y.H.; Tseng, L.M.; Chang, W.C.; King, K.L.; Chen, W.S.; Chiu, J.H.; Shyr, Y.M. **In vitro** demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab. **Menopause**, 2013, 20(6), 646-654.

[116] Lau, C.; Moomman, K.D.; Maas-Bakker, R.F.; Beijnen, J.H.; Schellens, J.H.; Meijer, I. Effect of Chinese herbs on CYP3A4 activity and expression **in vitro**. **J. Ethnopharmacol.**, 2013, 149(2), 543-549.

[117] Mukai, H.; Watanabe, T.; Ando, M.; Katsumata, N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. **Jpn. J. Clin. Oncol.**, 2006, 36(12), 808-810.

[118] Hwang, S.W.; Han, H.S.; Lim, K.Y.; Han, J.Y. Drug interaction between complementary herbal medicines and gefitinib. **J. Thorac. Oncol.**, 2008, 3(8), 942-943.

[119] Altan, E.; Bitik, B.; Kalpakci, Y.; Dogan, E.; Altundag, K. Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. **J. Altern. Complement. Med.**, 2009, 15(2), 113.

[120] Bromley, J.; Hughes, B.G.; Leong, D.C.; Buckley, N.A. Life threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. **Ann. Pharmacother.**, 2005, 39(9), 1566-1569.

[121] Noomhorm, N.; Chang, C.J.; Wen, C.S.; Wang, J.Y.; Chen, J.L.; Tseng, L.M.; Chen, W.S.; Chiu, J.H.; Shyr, Y.M. **In vitro** and **in vivo** effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen. **J. Pharmocol. Sci.**, 2014, 125(4), 375-385.

[122] Wu, X.M.; Wu, C.F. Network pharmacology: a new approach to unveiling Traditional Chinese Medicine. **Chin. J. Nat. Med.**, 2015, 13(1), 1-2.